186 related articles for article (PubMed ID: 21242851)
1. Ocular surface squamous neoplasia (squamous cell carcinoma) of the socket: management of extensive tumors with interferon.
Shields CL; Kancherla S; Bianciotto CG; Lally SE; Shields JA
Ophthalmic Plast Reconstr Surg; 2011; 27(4):247-50. PubMed ID: 21242851
[TBL] [Abstract][Full Text] [Related]
2. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
[TBL] [Abstract][Full Text] [Related]
3. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
4. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Sinha B; Kumar R
Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
6. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification.
Shields CL; Kaliki S; Kim HJ; Al-Dahmash S; Shah SU; Lally SE; Shields JA
Cornea; 2013 Mar; 32(3):248-56. PubMed ID: 22580436
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
[TBL] [Abstract][Full Text] [Related]
8. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
Galor A; Karp CL; Chhabra S; Barnes S; Alfonso EC
Br J Ophthalmol; 2010 May; 94(5):551-4. PubMed ID: 19493859
[TBL] [Abstract][Full Text] [Related]
9. Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.
Sripawadkul W; Reyes-Capo D; Zein M; Wylegala A; Albayyat G; Galor A; Karp CL
Ocul Surf; 2023 Apr; 28():108-114. PubMed ID: 36592780
[TBL] [Abstract][Full Text] [Related]
10. Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
Kaliki S; Bejjanki KM; Desai A; Mohamed A
Semin Ophthalmol; 2019; 34(7-8):465-472. PubMed ID: 31370766
[TBL] [Abstract][Full Text] [Related]
11. Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans.
Nava-Castañeda Á; Hernández-Orgaz J; Garnica-Hayashi L; Ansart A; Matus G; Tovilla-Canales JL
Nepal J Ophthalmol; 2018 Jul; 10(20):143-150. PubMed ID: 31056557
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Venkateswaran N; Mercado C; Galor A; Karp CL
Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
[TBL] [Abstract][Full Text] [Related]
14. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
Holcombe DJ; Lee GA
Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
[TBL] [Abstract][Full Text] [Related]
15. Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S; Sharma A; Vempuluru VS
Cornea; 2021 Feb; 40(2):142-146. PubMed ID: 32355112
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients.
Kaliki S; Singh S; Iram S; Tripuraneni D
Indian J Ophthalmol; 2016 Oct; 64(10):702-709. PubMed ID: 27905329
[TBL] [Abstract][Full Text] [Related]
17. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
Chaugule SS; Park J; Finger PT
Indian J Ophthalmol; 2018 Jan; 66(1):55-60. PubMed ID: 29283124
[TBL] [Abstract][Full Text] [Related]
18. Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment.
Leventer I; Singh H; Pashaee B; Raimondo CD; Khakh CK; Martin JL; Acharya B; Zhang Q; Lally SE; Shields CL
Asia Pac J Ophthalmol (Phila); 2024; 13(2):100052. PubMed ID: 38521390
[TBL] [Abstract][Full Text] [Related]
19. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration.
Shields CL; Constantinescu AB; Paulose SA; Yaghy A; Dalvin LA; Shields JA; Lally SE
Indian J Ophthalmol; 2021 Mar; 69(3):563-567. PubMed ID: 33595473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
